Mastocytosis results from a clonal proliferation of morphological and immunophenotypically abnormal mast cells. [1] [2] [3] [4] Extracutaneous involvement is commonly seen in adults, and the diagnosis of systemic mastocytosis (SM) is established as per World Health Organization (WHO) criteria. 5 Patients are frequently referred with episodic symptoms of 'mast cell activation' (MCA), wherein an underlying allergic or autoimmune disorder cannot be identified. 6, 7 In the absence of cutaneous involvement by mastocytosis, the next step typically is to determine whether SM is present. Increasingly, during such testing, patients who do not satisfy full diagnostic criteria for SM are identified; the major criterion (compact infiltrates of X15 mast cells) is not met; instead, only one or two minor criteria are met. Previous reports have implicated such patients in the context of idiopathic anaphylaxis or anaphylaxis following Hymenoptera sting, [8] [9] [10] however, the full spectrum of clinical presentation is currently not understood. Given the paucity of data regarding these patients, variously described as having monoclonal MCA syndrome (MMCAS) or pre-diagnostic indolent SM (ISM), [11] [12] [13] we sought to describe their clinicopathologic characteristics, and to compare them with ISM cases, or those with MCA symptoms without clonal mast cells.
This study was approved by the Mayo Clinic Institutional Review Board and adhered to the tenets of the Declaration of Helsinki. We retrospectively studied consecutive patients who were referred to our institution for evaluation for SM. Every patient had symptoms attributed by the referring physician as being related to mast cell degranulation. The diagnostic assessment included a bone marrow biopsy with tryptase immunostaining and mast cell immunophenotyping for CD25/CD2 expression by flow cytometry and/or immunohistochemistry. Bone marrow histology was reviewed by two experienced hematopathologists (DC and CAH) with careful assessment for mast cell cytologic atypia (for example, spindling or hypogranularity), presence or absence of mast cell aggregates (X15 mast cells) and pattern of mast cell infiltration (that is, compact clusters versus singly distributed/interstitial). KITD816V analysis was performed using a sensitive (0.01%) allelespecific PCR assay. 7, 14 The diagnosis and classification of SM was as per WHO criteria. 5 After a full review of clinicopathological characteristics, three groups were identified: 'sub-diagnostic SM' (that is, those meeting 1-2 minor criteria for SM only), ISM (that is, those meeting WHO diagnostic criteria for SM) and those with MCA symptoms without clonal mast cells. In the group with subdiagnostic SM, those with cutaneous mast cell infiltration (for example, urticaria pigmentosa) were excluded. Similarly, patients with non-ISM were also excluded from the study. A total of 83 patients were studied; 40 patients had ISM, 21 had sub-diagnostic SM and 22 had MCA symptoms without clonal mast cells. Clinical and laboratory characteristics at the time of referral are shown (Table 1 ).
In the ISM group, 63% exhibited cutaneous mast cell infiltration, 90% were KITD816V positive and 77% exhibited a baseline serum tryptase level 420 ng/ml (Table 1) . Thirty-three patients (83%) exhibited multifocal compact mast cell infiltrates in bone marrow biopsy sections plus at least one minor criterion, whereas the remainder satisfied X3 minor criteria.
In the sub-diagnostic SM group, none met the major SM diagnostic criterion (that is, compact mast cell infiltrates). Instead, the bone marrow mast cell infiltrate as identified by tryptase and in some cases CD117 immunostaining, was uniformly sparse with an interstitial distribution of individual mast cells (Figure 1) . The estimated mast cell burden was o5%, and more typically p1% of total marrow cellularity. Twelve patients (57%) demonstrated a population of overtly spindle-shaped mast cells and two patients (11%) had a baseline serum tryptase level of 420 ng/ml (Table 1 ). In terms of the WHO minor diagnostic criteria, 17 patients (81%) with sub-diagnostic SM met only one criterion (KITD816V alone ¼ 7 or mast cell CD25/CD2 expression alone ¼ 10). An additional four patients met two minor criteria (that is, KITD816V plus mast cell CD25/CD2 expression). Notably, three patients each did not undergo testing or had inconclusive results after screening for KITD816V or mast cell CD25/CD2 expression-here, even if the additional test were positive, criteria for SM would not have been met (that is, would have met o3 minor diagnostic criteria). A serum tryptase level above the normal range (X11.5 ng/ml) and 420 ng/ml was noted on at least one occasion during follow-up in 61% and 37% of sub-diagnostic Accepted article preview online 30 July 2013; advance online publication, 16 August 2013 Letters to the Editor SM patients, respectively. The higher levels were transiently observed, generally within the context of active mast cell degranulation symptoms.
A detailed inventory of patient-reported symptoms, as captured in the medical chart, is shown (Table 1 ). Sub-diagnostic SM patients had a significant symptom burden, in particular a high prevalence of cutaneous symptoms, abdominal pain/diarrhea, palpitations/syncope and angioedema/anaphylaxis with significant overlap with the two control groups (Table 1) . However, these patients did have a significantly higher prevalence of angioedema, wheezing, night sweats and self-reported environmental allergies (for example, pollen, grasses, animal hair/dander and foods) as compared with the other two groups. In contrast, osteopenia/ osteoporosis was significantly more frequent in ISM patients (Table 1 ). There were no significant differences among the three groups in terms of serious reactions to Hymenoptera sting, prevalence of eosinophilia or elevated immunoglobulin E levels, although the latter analysis was limited by the small number of patients studied. Finally, although baseline urine N-methylhistamine and 11b-prostaglandin F2a levels were increased above the normal range in 40-50% of sub-diagnostic SM patients, the absolute levels were significantly lower as compared with ISM patients (Table 1) .
We have described herein detailed clinicopathological characteristics of sub-diagnostic SM patients. The term 'subdiagnostic SM' may be more useful than 'MMCAS' because it is also relevant to those patients incidentally noted to have clonal mast cells in the bone marrow, without necessarily having MCA symptoms. Not surprisingly, the low burden of clonal mast cells in such cases was identified by high sensitivity (490%) tests, namely screening for KITD816V and/or mast cell CD25/CD2 expression. 15 In contrast, only 11% and 42% of patients had a baseline serum tryptase level 420 ng/ml and 4normal, respectively. Identification of patients on the basis of mast cell morphologic Letters to the Editor criteria alone was challenging given the subtle nature of the underlying bone marrow mast cell infiltrate. We identified a significant symptom burden in sub-diagnostic SM patients, beyond the prior descriptions of anaphylaxis associated with this entity. 8, 9 This suggests hyper responsiveness of mast cells as compared with ISM and, furthermore, indicates that sub-diagnostic SM may be a distinct clinicopathological entity given the uniform absence of compact bone marrow mast cell infiltrates. However, independent confirmation of our findings will be necessary. These data also have implications for the current WHO diagnostic criteria for SM; in this regard, consideration may be given as to whether fulfilling 1-2 minor criteria, in the appropriate clinical context, is sufficient for diagnosing 'low-burden SM'. A weakness of this study is lack of confirmation of minor criteria in some cases given the retrospective nature of the study. This is addressed by documentation of spindled mast cells in most of such cases. Finally, longer follow-up will be needed to fully ascertain the natural history of sub-diagnostic SM. Relapsed and refractory lymphoid and myeloid malignancies are often characterized by progressive resistance to standard chemotherapy as well as poor long-term outcomes. Additionally, many of the conventional treatment regimens may be accompanied by significant toxicity in this heavily pretreated population. Consequently, there is a need for novel therapies in these patients. Specific inhibition of essential signaling pathways offers potential for the design of rational therapeutic alternatives to cytotoxic chemotherapy. Among potential promising targets is casein kinase-2 (CK2), a highly conserved serine-threonine protein kinase comprised of two catalytic (a and a 0 ) and two regulatory (b) subunits. CK2 regulates a large number of critical signaling networks and downstream prosurvival and antiapoptotic substrates known to be essential to hematopoietic cell function. 1, 2 CK2 has been found to be overexpressed in many cancers, including hematologic malignancies such as chronic lymphocytic leukemia (CLL), 3 acute myeloid leukemia (AML), 4 T-cell acute lymphocytic leukemia (T-ALL) 5 and multiple myeloma. 6 Malignant cells are more dependent than normal tissues on upregulated levels of CK2 to sustain their growth and viability, 7 and elevated levels of CK2 have been found to correlate with inferior prognosis. 2 Consequently, despite its critical role in a diverse array of cellular processes, malignant cells are significantly more sensitive to CK2 downregulation; 2-9 potentially increasing its appeal as a therapeutic target.
CX-4945 is a selective, potent and orally bioavailable inhibitor of both isoforms of the CK2 catalytic subunits, and is the first smallmolecule inhibitor of CK2 to progress to human clinical trials. 9 Anti-tumor activity of CX-4945 has been validated in cancer cell lines and murine xenograft models, and biological activity has been observed in early phase clinical trials treating solid tumors. [9] [10] [11] However, little is known about its activity in leukemias and lymphomas. Therefore, using primary patient samples, we explored the therapeutic potential of CX-4945 across a wide spectrum of hematologic malignancies.
After informed consent, in accordance with the Declaration of Helsinki and approved by the institutional review board, Ficollpurified leukemia cells from 224 patients were cultured in the presence or absence of four serial dilutions of CX-4945 (Cylene Pharmaceuticals Inc., San Diego, CA, USA) ranging from 10 nM to 10 mM. Overall, 74 CLL, 60 AML, 58 B-cell acute lymphocytic leukemia, 13 chronic monomyelocytic leukemia (CMML), 4 T-ALL, 11 lymphoma and 4 chronic myeloid leukemia (CML) patients were included in the analysis. Purified leukemia cells were then cultured in RPMI þ 20% fetal bovine serum þ b-mercaptoethanol. A tetrazolium-based assay (MTS) was used to measure cell viability, which was then used to calculate IC 50 values.
Of the seven types of hematologic malignancies evaluated, all except CMML and CML demonstrated a subset of patients with significantly decreased viability (IC 50 o1 mM) in response to CX-4945 (Table 1 and Figure 1a) . Median IC 50 of all samples tested was 6.7 mM. CX-4945 appeared to be the most active in lymphoid malignancies, as this group contained the highest subset of sensitive patients (Table 1) . Of note, among the 16 sensitive CLL samples tested, 6 samples had an IC 50 o100 nm suggesting that there is a subset of samples that are highly sensitive to CK2 inhibition. Significant decreases in CLL cell viability in response to treatment with CX-4945 were observed in samples harboring a variety of high-risk features such as advanced Rai stage, CD38 and/or Zap 70 expression, unmutated variable region of the immunoglobulin heavy chain (IgV H ), chromosome 11q or17p Abbreviations: AML, acute myeloid leukemia; B-ALL, B-cell acute lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic monomyelocytic leukemia; CLL, chronic lymphocytic leukemia; T-ALL, T-cell acute lymphocytic leukemia. Median IC 50 of all samples tested was 6.7 mM.
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